8-K: Esperion Q3 2025 Revenue Soars 69%, Secures Patent Until 2040

Esperion Therapeutics reported a 69% year-over-year increase in total revenue for Q3 2025, reaching $87.3 million, and secured patent protection for its key products until April 2040.

Summary

• Total revenue for the third quarter of 2025 was $87.3 million, representing a 69% increase year-over-year.
• U.S. net product revenue for Q3 2025 grew 31% year-over-year to $40.7 million.
• Settlement agreements with four ANDA filers, including Dr. Reddys Laboratories, prevent generic versions of NEXLETOL and NEXLIZET from being marketed prior to April 2040.
• Bempedoic acid received a Class I, Level A recommendation in the 2025 ESC/EAS guidelines for the management of dyslipidemias.
• Partner Otsuka Pharmaceutical Co., Ltd. received regulatory approval and favorable preliminary pricing to market NEXLETOL in Japan, which will trigger significant milestone payments upon final pricing approval.
• Net loss for the three months ended September 30, 2025, was $31.3 million, compared to a net loss of $29.5 million for the comparable period in 2024.
• Net loss for the nine months ended September 30, 2025, was $84.5 million, compared to a net loss of $30.4 million for the comparable period in 2024.
• Cash and cash equivalents totaled $92.4 million as of September 30, 2025, down from $144.8 million as of December 31, 2024.
• Following the close of the quarter, the company raised approximately $72.6 million in net proceeds through a public stock offering.
• The company reiterates its expectation for full year 2025 operating expenses to be in the range of $215 million to $235 million.
• Esperion expects to achieve sustainable profitability beginning in the first quarter of 2026.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and secured long-term patent protection, which are significant positives. The global expansion and pipeline progress are also encouraging. However, the company continues to report net losses, and cash reserves decreased, necessitating a post-quarter capital raise. The increase in R&D and SG&A expenses, while tied to growth and litigation, contributes to the losses. The outlook for profitability in Q1 2026 is a strong positive, but it's still a forward-looking statement.

Positives

• Total revenue for Q3 2025 increased 69% year-over-year to $87.3 million, demonstrating robust growth.
• U.S. net product revenue for Q3 2025 grew 31% year-over-year to $40.7 million, driven by increased prescription volume and expanded payer coverage.
• Settlement agreements with four ANDA filers, including Dr. Reddys Laboratories, secure market exclusivity for NEXLETOL and NEXLIZET until April 2040.
• Bempedoic acid received a Class I, Level A recommendation in the 2025 ESC/EAS guidelines, a pivotal endorsement for cardiovascular risk management.
• Otsuka Pharmaceutical Co., Ltd. received regulatory approval and favorable preliminary pricing for NEXLETOL in Japan, expected to trigger significant milestone payments.
• Increased total retail prescription equivalents by approximately 9% and grew the number of healthcare practitioners writing prescriptions to more than 30,000 in Q3 2025.
• Achieved greater than 90% commercial lives and more than 80% Medicare beneficiaries covered for NEXLETOL and NEXLIZET.
• Royalty revenue increased 21% sequentially to $16.4 million, underscoring ongoing opportunity in Europe.
• Nominated ESP-2001, a highly specific allosteric ATP citrate lyase inhibitor, as a preclinical development candidate for primary sclerosing cholangitis (PSC), representing a potential blockbuster market opportunity of over $1 billion annually with no approved treatments.
• Economic model demonstrated that treatment with bempedoic acid provides improved lifetime CV risk reduction and a substantial net benefit, with a favorable incremental cost-effectiveness ratio (ICER) well below common U.S. thresholds.
• Expects to achieve sustainable profitability beginning in the first quarter of 2026.

Negatives

• Net loss for Q3 2025 increased to $31.3 million from $29.5 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, significantly increased to $84.5 million from $30.4 million in the comparable period of 2024.
• Total revenue for the nine months ended September 30, 2025, decreased 11% to $234.7 million from $263.2 million in 2024, primarily due to a large settlement agreement milestone received in 2024.
• Cash and cash equivalents decreased to $92.4 million as of September 30, 2025, from $144.8 million at December 31, 2024.
• Research and development expenses increased 36% in Q3 2025 to $14.1 million, primarily due to increased costs for ongoing clinical studies related to the pediatric program.
• Selling, general and administrative expenses increased 5% in Q3 2025 to $41.8 million, primarily due to increased legal costs associated with ANDA litigation and increased media costs.
• Bempedoic acid was associated with a higher incidence of gout in patients with elevated uric acid at baseline.

Risks

• Bempedoic acid may increase blood uric acid levels, which could lead to gout, particularly in patients with elevated uric acid at baseline.
• Bempedoic acid is associated with an increased risk of tendon rupture or injury, especially in patients over 60 years of age, those taking corticosteroids or fluoroquinolone drugs, patients with renal failure, and those with previous tendon disorders.
• There is a potential for serious adverse reactions in a breast-fed infant, therefore breastfeeding is not recommended during treatment with NEXLIZET or NEXLETOL.
• Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly, including those related to net sales, profitability, growth of commercial products, clinical activities, supply chain, commercial development and launch plans, and the outcomes of legal proceedings and settlements.

Future Outlook

Esperion reiterates its full-year 2025 operating expense guidance of $215 million to $235 million and expects to achieve sustainable profitability beginning in the first quarter of 2026. The company anticipates the inclusion of bempedoic acid in updated U.S. guidelines for dyslipidemias in early 2026, which, combined with extended patent runway, is expected to drive revenue growth and build a blockbuster franchise. Global partners are on track for market approvals and continued growth in Europe, Japan, Canada, Israel, Australia, and New Zealand. The company also plans to file an IND for ESP-2001 in 2026 to initiate first-in-human clinical studies for primary sclerosing cholangitis.

Management Comments

• "Our third quarter performance reflects consistently strong execution across our commercial, clinical, and global expansion strategies. We delivered robust year-over-year revenue growth, driven by increased U.S. prescription volume and expanded payer coverage, now reaching over 90% of commercial lives and more than 80% of Medicare lives." Sheldon Koenig, President and CEO.
• "The recent settlement agreement with Dr. Reddys, along with earlier settlements with three other ANDA filers, supports our ability to build and maintain our market leadership for many years to come." Sheldon Koenig, President and CEO.
• "The inclusion of bempedoic acid as a Class I, Level A recommendation in the 2025 ESC/EAS guidelines marks a pivotal moment in cardiovascular risk management. We believe this recognition will be reflected similarly in the upcoming U.S. guidelines expected in the first quarter of 2026." Sheldon Koenig, President and CEO.
• "In anticipation of this and our extended patent runway, throughout the third quarter we invested in enhanced payer access, expanded sales and marketing initiatives, and patient access programs to ensure that we are leveraging these advantages to drive revenue growth and build a blockbuster franchise." Sheldon Koenig, President and CEO.

Industry Context

The inclusion of bempedoic acid as a Class I, Level A recommendation in the 2025 ESC/EAS guidelines is a significant endorsement, positioning it strongly within the cardiovascular risk management landscape, especially for statin-intolerant patients. This aligns with a broader industry trend towards personalized medicine and addressing unmet needs in high-risk populations. The company's focus on statin intolerance with targeted marketing campaigns like "Cant take a statin? Make NEXLIZET happen!" capitalizes on a specific market segment. Global expansion efforts through partnerships in Europe, Japan, Canada, Israel, Australia, and New Zealand demonstrate a strategy to capture international market share for lipid-lowering therapies. The development of ESP-2001 for Primary Sclerosing Cholangitis (PSC), a condition with no approved treatments, positions Esperion in the rare disease space, which often offers significant market opportunities and potential for expedited regulatory pathways (Orphan Drug, Fast Track, PRIME designations).

Comparison to Industry Standards

• The Class I, Level A recommendation for bempedoic acid in the 2025 ESC/EAS guidelines places it among the highest-tier recommendations for dyslipidemia management, comparable to established therapies in terms of evidence strength and clinical benefit.
• The economic model showing bempedoic acid's incremental cost-effectiveness ratio (ICER) well below the U.S. threshold of <$150,000 per quality-adjusted life year (QALY) for the base case, and <$50,000 per QALY for the fixed-dose combination, indicates a strong value proposition compared to many new pharmaceutical interventions in the cardiovascular space.
• The settlement agreements extending patent protection until April 2040 provide a long runway for market exclusivity, a critical factor for biopharmaceutical companies, comparable to the extended patent lives of other successful blockbuster drugs.
• The potential for ESP-2001 to address a $1 billion+ annual market opportunity for Primary Sclerosing Cholangitis (PSC) with no approved treatments positions it similarly to other successful orphan drugs that have achieved significant market penetration due to high unmet medical need.

Management Changes

Legal Proceedings

• Reached settlement agreements with four ANDA filers, including Dr. Reddys Laboratories, preventing them from marketing generic versions of NEXLETOL and NEXLIZET prior to April 2040.
• Increased legal costs associated with the ANDA litigation contributed to higher SG&A expenses in Q3 2025.

Stakeholder Impact

• Shareholders: Positive impact from extended patent protection, strong revenue growth, global expansion, and future profitability outlook. Dilution from the post-quarter public stock offering.
• Patients: Improved access to NEXLETOL and NEXLIZET through expanded payer coverage and patient support programs. Stronger clinical validation with Class I, Level A recommendation in ESC/EAS guidelines. Potential for new treatment options for PSC with ESP-2001.
• Healthcare Providers: Enhanced clinical guidance with ESC/EAS recommendation, supporting increased prescription writing.
• Employees: Continued growth and strategic investments suggest stability and potential for expansion.
• Partners (Daiichi Sankyo Europe, Otsuka, HLS Therapeutics, Neopharm Israel, CSL Seqirus): Continued collaboration revenue, milestone payments, and market expansion opportunities.

Next Steps

• Host a virtual investor Key Opinion Leader Event on November 11, 2025, focusing on bempedoic acid for statin intolerant patients.
• Anticipate the inclusion of bempedoic acid in the updated U.S. guidelines for the management of dyslipidemias in early 2026.
• Continue to leverage enhanced payer access, expanded sales and marketing initiatives, and patient access programs.
• HLS Therapeutics expects market approval for NEXLETOL and NEXLIZET in Canada by year-end 2025.
• Neopharm Israel expects regulatory approval to market NEXLETOL and NEXLIZET in Israel in the first half of 2026.
• CSL Seqirus expects market approval for NEXLETOL and NEXLIZET in Australia in Q4 2026.
• File an Investigational New Drug (IND) application with the U.S. FDA to initiate first-in-human clinical studies for ESP-2001 in 2026.
• Achieve sustainable profitability beginning in the first quarter of 2026.

Key Dates

Recommendation

The strong Q3 2025 revenue growth, particularly in U.S. net product sales, indicates robust commercial momentum. The critical settlement agreements extending patent exclusivity for NEXLETOL and NEXLIZET until 2040 significantly de-risk the company's core assets and provide a long runway for future revenue generation. The Class I, Level A recommendation in the ESC/EAS guidelines is a major clinical validation, expected to drive further adoption and market share, especially with anticipated similar U.S. guideline updates. While the company is currently operating at a net loss, the reiterated guidance for sustainable profitability in Q1 2026, coupled with the post-quarter capital raise strengthening the balance sheet, provides a clear path to financial health. The promising preclinical pipeline candidate ESP-2001 for PSC also offers significant long-term growth potential in an unmet medical need area. These factors collectively suggest a strong investment case for long-term growth.

Keywords

Esperion Therapeutics, ESPR, NEXLETOL, NEXLIZET, bempedoic acid, ezetimibe, hypercholesterolemia, cardiovascular disease, statin intolerance, lipid-lowering, Q3 2025 earnings, financial results, biopharmaceutical, patent settlement, ANDA litigation, Otsuka, Daiichi Sankyo Europe, ESC/EAS guidelines, FDA, Orphan Drug, Fast Track, ATP citrate lyase inhibitor, primary sclerosing cholangitis, PSC